Please Wait.....
Report
NA Pancreatic Cancer Diagnostics Market - Industry Trends and Forecast to 2030
Market Report I 2023-01-01 I 292 Pages I Data Bridge Market Research
The North America pancreatic cancer diagnostics market is projected to register a substantial CAGR of 7.7% from 2023 to 2030. The new market report contains data for the historic year 2020, the base year of calculation is 2021, and the forecast period is 2023 to 2030.
Market Segmentation:
North America Pancreatic Cancer Diagnostics Market, By Test Type (Imaging Test, Biopsy, Blood Test, Genomic Test, and Others), Cancer Stage (Stage 0, Stage I, Stage II, Stage III and Stage IV), Tumor Type(Exocrine Tumors and Neuroendocrine Tumors), Product (Instrument-Based Products, Platform-Based Products, Kits and Reagents, and Other Consumables), Technology (Fluorescent In Situ Hybridization, Next Generation Sequencing, Fluorimmunoassay, Comparative Genomic Hybridization, Immunohistochemical, and Others), Application(Screening, Diagnostic and Predictive, Prognostic, and Research), End User (Hospitals, Diagnostic Centers, Cancer Research Centers, Academic Institutes, Ambulatory Surgical Centers, and Others), Distribution Channel (Direct Tender, Retail Sales and Others), Country (U.S., Canada, Mexico) Industry Trends and Forecast to 2030
Some of the major factors contributing to the growth of pancreatic cancer diagnostics market are:
- Rise in prevalence and incidence of pancreatic cancer
- Increase in awareness about the pancreatic cancer diagnostics
Market Players:
Some of the major players operating in the North America pancreatic cancer diagnostics market are:
- Canon Medical Systems ANZ Pty Limited.
- Koninklijke Philips N.V.
- Siemens Healthcare Private Limited
- Grail
- Myriad Genetics, Inc.
- BD
- Abbott
- FUJIFILM Holdings America Corporation
- Agilent Technologies, Inc.
- Thermo Fisher Scientific
- QIAGEN
- MP BIOMEDICALS
- Laboratory Corporation of America Holdings
- CTK Biotech, Inc.
- Creative Biolabs
- Meridian Life Science, Inc.
- Lee Biosolutions, Inc
TABLE OF CONTENTS
1 INTRODUCTION 91
1.1 OBJECTIVES OF THE STUDY 91
1.2 MARKET DEFINITION 91
1.3 OVERVIEW OF THE NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET 91
1.4 CURRENCY AND PRICING 94
1.5 LIMITATIONS 94
1.6 MARKETS COVERED 94
2 MARKET SEGMENTATION 98
2.1 MARKETS COVERED 98
2.2 GEOGRAPHICAL SCOPE 99
2.3 YEARS CONSIDERED FOR THE STUDY 100
2.4 DBMR TRIPOD DATA VALIDATION MODEL 101
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 104
2.6 MULTIVARIATE MODELLING 105
2.7 MARKET END USER COVERAGE GRID 106
2.8 PRODUCT LIFELINE CURVE 107
2.9 DBMR MARKET POSITION GRID 108
2.10 VENDOR SHARE ANALYSIS 109
2.11 SECONDARY SOURCES 110
2.12 ASSUMPTIONS 110
3 EXECUTIVE SUMMARY 111
4 PREMIUM INSIGHTS 114
4.1 PESTEL ANALYSIS 115
4.2 PORTER'S FIVE FORCES MODEL 116
5 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET, INDUSTRY INSIGHTS 117
6 EPIDEMIOLOGY 119
7 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET, REGULATIONS 120
8 MARKET OVERVIEW 123
8.1 DRIVERS 125
8.1.1 GROW IN PREVALENCE OF PANCREATIC CANCER 125
8.1.2 NOVEL TECHNOLOGICAL ADVANCEMENTS IN PANCREATIC DIAGNOSTICS 125
8.1.3 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UPS 126
8.1.4 INCREASE IN AWARENESS REGARDING PANCREATIC CANCER 126
8.2 RESTRAINTS 127
8.2.1 STRICT REGULATIONS AND STANDARDS FOR THE APPROVAL AND COMMERCIALIZATION OF PANCREATIC CANCER DIAGNOSTIC PRODUCTS 127
8.2.2 LATE DIAGNOSIS AND POOR PROGNOSIS OF PANCREATIC CANCER 127
8.3 OPPORTUNITIES 128
8.3.1 INCREASE IN DIAGNOSTIC PRODUCTS FOR PANCREATIC CANCER 128
8.3.2 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT 129
8.3.3 GOVERNMENT INITIATIVES TOWARD PANCREATIC CANCER DIAGNOSTICS 129
8.4 CHALLENGES 130
8.4.1 INCREASED COST, SAFETY, AND CONVENIENCE ISSUES 130
8.4.2 LACK OF SKILLED AND CERTIFIED PROFESSIONALS 130
9 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE 131
9.1 OVERVIEW 132
9.2 IMAGING TEST 135
9.2.1 COMPUTED TOMOGRAPHY (CT) SCAN 136
9.2.2 MAGNETIC RESONANCE IMAGING (MRI) 136
9.2.2.1 MR CHOLANGIOPANCREATOGRAPHY 136
9.2.2.2 MR ANGIOGRAPHY (MRA) 137
9.2.3 ULTRASOUND 137
9.2.3.1 ABDOMINAL ULTRASOUND 137
9.2.3.2 ENDOSCOPIC ULTRASOUND (EUS) 137
9.2.4 CHOLANGIOPANCREATOGRAPHY 137
9.2.4.1 MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY (MRCP) 138
9.2.4.2 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY (ERCP) 138
9.2.4.3 PRECUTANEOUS TRANSHEPTIC CHOLANGIOPANCREATOGRAPHY (PTC) 138
9.2.5 POSITRON EMISSION TOMOHRAPHY (PET) 138
9.2.6 OTHERS 138
9.3 BIOPSY 139
9.3.1 CT-GUIDED NEEDLE BIOPSY 140
9.3.2 FINE NEEDLE ASPIRATION (FNA) 140
9.3.3 CORE NEEDLE BIOPSY 140
9.3.4 OTHERS 140
9.4 BLOOD TEST 140
9.4.1 LIVER FUNCTION TEST 141
9.4.2 TUMOR MARKER 141
9.4.2.1 CA 19-9 BIOMARKER TEST 142
9.4.2.2 CARCINOEMBROYNIC ANTIGEN (CEA) TEST 142
9.4.2.3 CA 50 MARKER TEST 142
9.4.2.4 OTHERS 142
9.4.3 OTHERS 142
9.5 GENOMIC TEST 143
9.6 OTHERS 144
10 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGES 145
10.1 OVERVIEW 146
10.2 STAGE IV 149
10.3 STAGE III 149
10.4 STAGE II 150
10.4.1 STAGE IIA 151
10.4.2 STAGE IIB 151
10.5 STAGE I 151
10.5.1 STAGE IA 152
10.5.2 STAGE IB 152
10.6 STAGE 0 153
11 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE 154
11.1 OVERVIEW 155
11.2 EXOCRINE TUMORS 158
11.2.1 INSTRUMENT-BASED PRODUCTS 159
11.2.2 PLATFORM-BASED PRODUCTS 159
11.2.3 KITS AND REAGENTS 159
11.2.4 OTHER CONSUMABLES 159
11.3 NEUROENDOCRINE TUMORS 159
11.3.1 INSTRUMENT-BASED PRODUCTS 160
11.3.2 PLATFORM-BASED PRODUCTS 160
11.3.3 KITS AND REAGENTS 161
11.3.4 OTHER CONSUMABLES 161
12 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT 162
12.1 OVERVIEW 163
12.2 INSTRUMENT-BASED PRODUCTS 166
12.2.1 IMAGING 167
12.2.2 BIOPSY 167
12.3 PLATFORM-BASED PRODUCTS 167
12.3.1 NEXT-GENERATION SEQUENCING 168
12.3.2 MICROARRAYS 168
12.3.3 PCR 168
12.3.4 OTHERS 169
12.4 KITS AND REAGENTS 169
12.4.1 CA19-9 PANCREATIC CANCER TEST KITS 170
12.4.1.1 ELISA TEST KITS 170
12.4.1.2 CASETTE TEST KITS 170
12.4.1.3 OTHERS 170
12.4.2 CEA PANCREATIC CANCER TEST KITS 171
12.4.2.1 ELISA TEST KITS 171
12.4.2.2 CASETTE TEST KITS 171
12.4.2.3 OTHERS 171
12.5 OTHER CONSUMABLES 171
13 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY 173
13.1 OVERVIEW 174
13.2 FLUORESCENT IN SITU HYBRIDIZATION 177
13.3 NEXT GENERATION SEQUENCING 178
13.4 FLUORIMMUNOASSAY 179
13.5 COMPARATIVE GENOMIC HYBRIDIZATION 180
13.6 IMMUNOHISTOCHEMICAL 181
13.7 OTHERS 182
14 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION 183
14.1 OVERVIEW 184
14.2 SCREENING 187
14.2.1 INSTRUMENT-BASED PRODUCTS 188
14.2.2 PLATFORM-BASED PRODUCTS 188
14.2.3 KITS AND REAGENTS 188
14.2.4 OTHER CONSUMABLES 188
14.3 DIAGNOSTIC AND PREDICTIVE 188
14.3.1 INSTRUMENT-BASED PRODUCTS 189
14.3.2 PLATFORM-BASED PRODUCTS 189
14.3.3 KITS AND REAGENTS 189
14.3.4 OTHER CONSUMABLES 189
14.4 PROGNOSTIC 190
14.4.1 INSTRUMENT-BASED PRODUCTS 191
14.4.2 PLATFORM-BASED PRODUCTS 191
14.4.3 KITS AND REAGENTS 191
14.4.4 OTHER CONSUMABLES 191
14.5 RESEARCH 191
14.5.1 INSTRUMENT-BASED PRODUCTS 192
14.5.2 PLATFORM-BASED PRODUCTS 192
14.5.3 KITS AND REAGENTS 192
14.5.4 OTHER CONSUMABLES 192
15 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER 193
15.1 OVERVIEW 194
15.2 HOSPITALS 197
15.3 DIAGNOSTIC CENTERS 197
15.4 CANCER RESEARCH CENTERS 198
15.5 ACADEMIC INSTITUTES 199
15.6 AMBULATORY SURGICAL CENTERS 200
15.7 OTHERS 201
16 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 202
16.1 OVERVIEW 203
16.2 DIRECT TENDER 206
16.3 RETAIL SALES 207
16.4 OTHERS 208
17 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION 209
17.1 NORTH AMERICA 210
17.1.1 U.S. 224
17.1.2 CANADA 233
17.1.3 MEXICO 242
18 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET: COMPANY LANDSCAPE 251
18.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 251
19 SWOT ANALYSIS 252
20 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET 253
20.1 CANON MEDICAL SYSTEMS CORPORATION 253
20.1.1 COMPANY SNAPSHOT 253
20.1.2 REVENUE ANALYSIS 253
20.1.3 COMPANY SHARE ANALYSIS 254
20.1.4 PRODUCT PORTFOLIO 254
20.1.5 RECENT DEVELOPMENT 254
20.2 KONINKLIJKE PHILIPS N.V. 255
20.2.1 COMPANY SNAPSHOT 255
20.2.2 REVENUE ANALYSIS 255
20.2.3 COMPANY SHARE ANALYSIS 256
20.2.4 PRODUCT PORTFOLIO 256
20.2.5 RECENT DEVELOPMENTS 256
20.3 SIEMENS HEALTHCARE GMBH 258
20.3.1 COMPANY SNAPSHOT 258
20.3.2 REVENUE ANALYSIS 258
20.3.3 COMPANY SHARE ANALYSIS 259
20.3.4 PRODUCT PORTFOLIO 259
20.3.5 RECENT DEVELOPMENT 260
20.4 GRAIL 261
20.4.1 COMPANY PROFILE 261
20.4.2 COMPANY SHARE ANALYSIS 261
20.4.3 PRODUCT PORTFOLIO 262
20.4.4 RECENT DEVELOPMENT 262
20.5 MYRIAD GENETICS, INC. 263
20.5.1 COMPANY SNAPSHOT 263
20.5.2 REVENUE ANALYSIS 263
20.5.3 COMPANY SHARE ANALYSIS 264
20.5.4 PRODUCT PORTFOLIO 264
20.5.5 RECENT DEVELOPMENT 264
20.6 BD 265
20.6.1 COMPANY SNAPSHOT 265
20.6.2 REVENUE ANALYSIS 265
20.6.3 PRODUCT PORTFOLIO 266
20.6.4 RECENT DEVELOPMENT 266
20.7 BODITECH MED INC. 267
20.7.1 COMPANY PROFILE 267
20.7.2 PRODUCT PORTFOLIO 267
20.7.3 RECENT DEVELOPMENT 267
20.8 ABBOTT (2022) 268
20.8.1 COMPANY SNAPSHOT 268
20.8.2 REVENUE ANALYSIS 268
20.8.3 PRODUCT PORTFOLIO 269
20.8.4 RECENT DEVELOPMENT 269
20.9 FUJIFILM HOLDINGS AMERICA CORPORATION 270
20.9.1 COMPANY SNAPSHOT 270
20.9.2 REVENUE ANALYSIS 270
20.9.3 PRODUCT PORTFOLIO 271
20.9.4 RECENT DEVELOPMENT 271
20.10 ACCUBIOTECH CO., LTD. 272
20.10.1 COMPANY PROFILE 272
20.10.2 PRODUCT PORTFOLIO 272
20.10.3 RECENT DEVELOPMENTS 272
20.11 AGILENT TECHNOLOGIES, INC. 273
20.11.1 COMPANY PROFILE 273
20.11.2 REVENUE ANALYSIS 273
20.11.3 PRODUCT PORTFOLIO 274
20.11.4 RECENT DEVELOPMENT 274
20.12 CREATIVE BIOLABS. 275
20.12.1 COMPANY PROFILE 275
20.12.2 PRODUCT PORTFOLIO 275
20.12.3 RECENT DEVELOPMENT 275
20.13 CTK BIOTECH, INC. 276
20.13.1 COMPANY PROFILE 276
20.13.2 PRODUCT PORTFOLIO 276
20.13.3 RECENT DEVELOPMENT 276
20.14 DIASOURCE 277
20.14.1 COMPANY SNAPSHOT 277
20.14.2 PRODUCT PORTFOLIO 277
20.14.3 RECENT DEVELOPMENT 277
20.15 LABORATORY CORPORATION OF AMERICA HOLDINGS 278
20.15.1 COMPANY SNAPSHOT 278
20.15.2 REVENUE ANALYSIS 278
20.15.3 PRODUCT PORTFOLIO 279
20.15.4 RECENT DEVELOPMENTS 279
20.16 LEE BIOSCIENCE 280
20.16.1 COMPANY SNAPSHOT 280
20.16.2 PRODUCT PORTFOLIO 280
20.16.3 RECENT DEVELOPMENT 280
20.17 MERIDIAN BIOSCIENCE INC. 281
20.17.1 COMPANY PROFILE 281
20.17.2 PRODUCT PORTFOLIO 281
20.17.3 RECENT DEVELOPMENT 281
20.18 MP BIOMEDICALS. 282
20.18.1 COMPANY PROFILE 282
20.18.2 PRODUCT PORTFOLIO 282
20.18.3 RECENT DEVELOPMENTS 282
20.19 QIAGEN 283
20.19.1 COMPANY SNAPSHOT 283
20.19.2 REVENUE ANALYSIS 283
20.19.3 PRODUCT PORTFOLIO 284
20.19.4 RECENT DEVELOPMENT 284
20.20 SETIA SCIENTIFIC SOLUTION 285
20.20.1 COMPANY PROFILE 285
20.20.2 PRODUCT PORTFOLIO 285
20.20.3 RECENT DEVELOPMENTS 285
20.21 THERMO FISHER SCIENTIFIC INC. 286
20.21.1 COMPANY SNAPSHOT 286
20.21.2 REVENUE ANALYSIS 286
20.21.3 PRODUCT PORTFOLIO 287
20.21.4 RECENT DEVELOPMENT 287
21 QUESTIONNAIRE 288
22 RELATED REPORTS 292
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security